


Pending claims after amendment – clean version

1. (Amended) A method for treating a condition related to angiogenesis, said method comprising administering to a patient in need of such treatment an effective amount of a compound having the general formula Ia



wherein R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl, C_{1-6} -alkoxy, hydroxy, NR^7R^8 , cyano, methylthio or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; or

Y is $-\underline{CH_2N}(-)CH_2-$, $-\underline{CH_2N}(-)CH_2-$, $-(\underline{C=O})N(-)CH_2-$, $-\underline{CH_2N}(-)(\underline{C=O})-$, $-\underline{CH_2CH}(-)CH_2-$, $-\underline{CH_2CH}(-)CH_2-$, $-\underline{CH_2C}(-)=CH-$, $-\underline{CH}=\underline{C}(-)CH_2-$, $-\underline{OCH}(-)CH_2-$, $-\underline{CH_2CH}(-)O-$, $-\underline{SCH}(-)CH_2-$, $-\underline{CH_2CH}(-)S-$, wherein only the underscored atom participates in the ring system; or

Y is $>\underline{N}-$, $>\underline{CH}-$, $>\underline{N}-(C=O)-$ or $>\underline{C}=C(R^8)-$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; or

Y is $>\underline{CH}-O-$ or $>\underline{CH}-S(O)_y$ wherein y is 0, 1 or 2, or $-N(R^8)-$ wherein R^8 is hydrogen or C_{1-6} -alkyl, and wherein only the underscored atom participates in the ring system; and


X is completion of an optional bond, ortho-phenylene, $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-CH_2OCH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$

, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q independently are 0 or 1; and

r is 0, 1, 2, 3 or 4; and


Z is selected from



wherein R⁶ is OH or C₁₋₆-alkoxy; and

.... is optionally a single bond or a double bond; or

Z is selected from



wherein n is 1 or 2;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen,

trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

.... is optionally a single bond or a double bond; or

Z is selected from



wherein u is 0 or 1;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein


R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10a} is hydrogen or C_{1-6} -alkyl; and

A is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; or

Z is selected from




wherein M_1 and M_2 independently are C or N; and

R^{35} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{33} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


R^{34} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_wCOR^{31}$, $-(CH_2)_wOH$ or $-(CH_2)_wSO_2R^{31}$ wherein R^{31} is hydroxy, C_{1-6} -alkoxy or NHR^{32} , wherein R^{32} is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or

R^{34} is selected from



; or


Z is



wherein b is 0, 1, 2, 3 or 4; and

B is $-\text{CH}=\text{CR}^{49}-$, $-\text{CR}^{49}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{CH}_2)-$, $-(\text{CR}^{49}\text{R}^{40})-$, $-\text{CH}(\text{OR}^{41})-$, $-\text{CH}(\text{NHR}^{41})-$, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and


U is



wherein R^{42} is hydrogen, $-(\text{CH}_2)_c\text{OH}$ or $-(\text{CH}_2)_d\text{COR}^{47}$ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein R^{47} is $-\text{OH}$, $-\text{NHR}^{44}$ or C_{1-6} -alkoxy wherein R^{44} is hydrogen or C_{1-6} -alkyl; and

R^{43} is cyano, $-\text{NR}^{45}\text{R}^{47}$, $-\text{NR}^{45}-\text{V}$ or $-(\text{CHR}^{48})_e-\text{V}$ wherein R^{45} and R^{47} independently are hydrogen or C_{1-6} -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R^{48} is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-\text{NR}^{45}\text{R}^{47}$ or $-\text{COOH}$, and wherein V is C_{3-8} -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio, C_{1-6} -alkyl or C_{1-6} -alkoxy; or

U is selected from



wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and

wherein R^{17u} is -OH, -NHR^{20u} or C₁₋₆-alkoxy wherein R^{20u} is hydrogen or C₁₋₆-alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{14u} is hydrogen or C₁₋₆-alkyl; and

C is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene; and

... is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M₁ and M₂ independently are C or N; and

R^{19u} is hydrogen, C₁₋₆-alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH₂)_kCOR^{17u}, -(CH₂)_kOH or - (CH₂)_kSO₂R^{17u} wherein k is 0, 1 or 2; or

R^{16u} is selected from




; or

Z is selected from



wherein R⁵³ is -(CH₂)_{pp}COOH wherein pp is 2, 3, 4, 5 or 6; or

Z is




wherein tt and t independently are 0, 1 or 2; and

R⁶³ is H, C₁₋₆-alkyl or optionally substituted benzyl;

R⁶⁴ and R⁶⁵ independently are H, C₁₋₈-alkyl, C₃₋₇-cycloalkyl, phenyl, thienyl, benzyl, or R⁶⁴ and R⁶⁵ together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

R⁶⁶ is H or C₁₋₆-alkyl; or


Z is selected from



wherein D is -CH₂-, -O-, -S- or -N(R⁷)- wherein R⁷ is hydrogen or C₁₋₆-alkyl; and

R^{3m} is -(CH₂)_{mm}OH or -(CH₂)_{mp}COR⁴ wherein mm and mp are 1, 2, 3 or 4 and R⁴ is OH, NH₂, NHOH or C₁₋₆-alkoxy; or

having the general formula Ib



(Ib)

wherein R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy,


C₁₋₆-alkyl or C₁₋₆-alkoxy; and


R^{3b} is hydrogen or C₁₋₃-alkyl; and

A_b is C₁₋₃-alkylene; and

Y_b is >CH-CH₂-, >C=CH-, >CH-O-, >C=N-, >N-CH₂- wherein only the underscored atom participates in the ring system; and

Z_b is selected from





wherein nb is 1 or 2; and

R^{11b} is hydrogen or C_{1-6} -alkyl; and

R^{12b} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoro-methyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14b} is $-(CH_2)_{mb}OH$ or $-(CH_2)_{tb}COR^{15b}$ wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein R^{15b} is $-OH$, NH_2 , $-NHOH$ or C_{1-6} -alkoxy; and

R^{16b} is C_{1-6} -alkyl or $-B_b-COR^{15b}$, wherein B_b is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15b} is the same as above; and

... is optionally a single bond or a double bond; or

having the general formula Ic




wherein R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

X_c is ortho-phenylene, -O-, -S-, $-C(R^{6c}R^{7c})-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^{8c})-(C=O)-$, $-(C=O)-N(R^{8c})-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^{8c})-$, $-N(R^{8c})(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^{10c})CH_2-$, $-CH_2CH(R^{10c})-$, $-(C=O)-$, $-N(R^{9c})-$ or $-(S=O)-$ wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl;
 Y_c is C or N;

.... is optionally a single bond or a double bond, and is a single bond when Y_c is N;


mc is 1, 2, 3, 4, 5 or 6; and

Z_c is $-COOR^{3c}$ or



wherein R^{3c} is H or C_{1-6} -alkyl; or

having the general formula Id




(Id)

wherein R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

X_d is -O-, -S- or -S(=O)-; and

rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 ; and

Z_d is selected from



wherein R^{3d} is $-(CH_2)_{md}OH$ or $-(CH_2)_{pd}COR^{4d}$ wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or

a pharmaceutically acceptable salt of any of the foregoing.

2. (Amended) The method according to claim 1 wherein the condition is related to cancer.

3. (Amended) The method according to claim 1 wherein the condition is related to ocular neovascularization.

4. (Amended) The method according to claim 1 wherein, in formula Ia, R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -O-CH₂-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

p and q are 0, and

r is 1, 2 or 3; and

Z is selected from



wherein R⁶ is OH or C₁₋₆-alkoxy; and

... is optionally a single bond or a double bond; and

a pharmaceutically acceptable salt of any of the foregoing.

5. (Amended) The method according to claim 4 wherein the compound is selected from the group consisting of:

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;

(R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride,

[or] and a pharmaceutically acceptable salt [thereof] of any of the foregoing.

6. (Amended) The method according to claim 1 wherein, in formula Ia,

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and


Y is -CH₂N(-)CH₂-, -CH₂N(-)CH₂-, -(C=O)N(-)CH₂-, -CH₂N(-)(C=O)-, -CH₂CH(-)CH₂-, -CH₂CH(-)CH₂-, -CH₂C(-)=CH-, -CH=C(-)CH₂-, -OCH(-)CH₂-, -CH₂CH(-)O-, -SCH(-)CH₂-, -CH₂CH(-)S-, wherein only the underscored atom participates in the ring system; and

X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -S-CH₂-, -CH₂-S-, -N(R⁸)-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

p and q independently are 0 or 1; and

r is 1, 2 or 3; and

Z is selected from



wherein R⁶ is OH or C₁₋₆-alkoxy; and

.... is optionally a single bond or a double bond; and

a pharmaceutically acceptable salt of any of the foregoing.

7. (Amended) The method according to claim 6 wherein the compound is selected from the group consisting of:

(R)-1-(3-(6,11-Dioxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5,11-Dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenzo[b,f][1,4]thiazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxathiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenzo[b,e][1,4]dithiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,e][1,4]oxathiepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-10H-dibenz[b,g][1,5]oxazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-10H-dibenzo[b,g][1,5]thiazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(11,12-Dihydro-6H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(11,12-Dihydro-5H-dibenzo[a,e]cycloocten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(7,12-Dihydro-6H-dibenzo[a,d]cycloocten-6-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5-Methyl-5,11-dihydro-dibenz[b,f]azepin-10-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Oxo-5,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5,6,11,12-Tetrahydro-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Methyl-dibenz[b,f]azepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenz[b,g][1,5]oxazocin-6-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-dibenz[a,e]cycloocten-5-yl)-1-propyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

8. (Amended) The method according to claim 1 wherein, in formula Ia,

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, NR^7R^8 , hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and


Y is $\text{>N-CH}_2\text{-}$, $\text{>CH-CH}_2\text{-}$ or >C=CH- wherein only the underscored atom participates in the ring system; and

X is -O- , -S- , $\text{-C(R}^7\text{R}^8\text{)-}$, $\text{-CH}_2\text{CH}_2\text{-}$, $\text{-CH=CH-CH}_2\text{-}$, $\text{-CH}_2\text{-CH=CH-}$, $\text{-CH}_2\text{-(C=O)-}$, $\text{-(C=O)-CH}_2\text{-}$, $\text{-CH}_2\text{CH}_2\text{CH}_2\text{-}$, -CH=CH- , $\text{-N(R}^8\text{)-(C=O)-}$, $\text{-(C=O)-N(R}^8\text{)-}$, $\text{-O-CH}_2\text{-}$, $\text{-CH}_2\text{-O-}$, $\text{-S-CH}_2\text{-}$, $\text{-CH}_2\text{-S-}$, $\text{-N(R}^8\text{)-}$, -(C=O)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



wherein n is 1 or 2; and

R^3 is $\text{-(CH}_2\text{)}_m\text{OH}$ or $\text{-(CH}_2\text{)}_s\text{COR}^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein R^4 is -OH , -NH_2 , -NHOH or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

.... is optionally a single bond or a double bond; and
a pharmaceutically acceptable salt of any of the foregoing.

9. (Amended) The method according to claim 8 wherein the compound is selected from the group consisting of:

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidine-carboxamide;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperidinecarboxylic acid;

(1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinyl)methanol;

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinol;

4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

(2S,4R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-hydroxy-2-pyrrolidinecarboxylic acid;

4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-morpholinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-aziridinecarboxylic acid;

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-methyl-[1,4]-diazepane-6-carboxylic acid;

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid
hydroxamide;

(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)piperazin-1-yl)acetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-
piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-
piperidinecarboxamide;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-
pyrrolidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-
pyrrolidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-
piperidinecarboxylic acid;

1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic
acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-methyl-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-quinuclidiniumcarboxylate;

1-(3-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3,7-Dimethyl-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Dimethylamino-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-2-piperidineacetic acid;

1-(3-(Phenothiazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-2-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(6,11-Dihydrodibenzo[b,e]oxepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

10. (Amended) The method according to claim 1 wherein in, formula Ia,

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$, $\text{>}\underline{\text{C}}\text{H-CH}_2\text{-}$ or $\text{>}\underline{\text{C}}\text{=CH-}$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, $\text{-CH}_2\text{-(C=O)-}$, $\text{-(C=O)-CH}_2\text{-}$, $\text{-S-CH}_2\text{-}$, $\text{-CH}_2\text{-S-}$, $\text{-(CH}_2\text{)N(R}^8\text{)-}$, $\text{-N(R}^8\text{)(CH}_2\text{)-}$, $\text{-N(CH}_3\text{)SO}_2\text{-}$, $\text{-SO}_2\text{N(CH}_3\text{)-}$, $\text{-CH(R}^9\text{)CH}_2\text{-}$ or $\text{-CH}_2\text{CH(R}^9\text{)-}$ wherein R^8 is hydrogen or C_{1-6} -alkyl and R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



wherein R^6 is OH or C_{1-6} -alkoxy; and

.... is optionally a single bond or a double bond;

and a pharmaceutically acceptable salt of any of the foregoing.

11. (Amended) The method according to claim 10 wherein the compound is selected from the group consisting of:

1-(3-(9H-Tribenz[b,d,f]azepin-9-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Methyl-6H-dibenzo[c,f][1,2]thiazepin-5,5-dioxide-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Methyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Phenyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6,11-Dihydro-11H-dibenzo[b,e][1,4]thiazepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Methyl-10,11-dihydro-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10-Oxo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6-Methyl-6,11-dihydro-dibenzo[c,f][1,2,5]thiadiazepin-5,5-dioxide-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[b,d,f]azepine-9-yl)propyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

12. (Amended) The method according to claim 1 wherein, in formula Ia,

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

Y is >N-CH₂-, >CH-CH₂- or >C=CH- wherein only the underscored atom participates in the ring system; and


X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -S-CH₂-, -

CH₂-S-, -N(R⁸)-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



wherein u is 0 or 1;

R³ is -(CH₂)_mOH or -(CH₂)_sCOR⁴ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R⁴ is -OH, -NH₂, -NHOH or C₁₋₆-alkoxy; and

R⁵ is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{10a} is hydrogen or C₁₋₆-alkyl; and

A is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene; and

a pharmaceutically acceptable salt of any of the foregoing.

13. (Amended) The method according to claim 12 wherein the compound is selected from the group consisting of:

3-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)propionic acid;

4-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)butyric acid;

3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)propionic acid;

2-(N(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methyl-amino)succinic acid;

2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

2-(N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)nicotinic acid;

2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)methyl)benzoic acid;

2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)-1-cyclohexanecarboxylic acid;

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propylamino)pyridin-3-ol;

3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

2-((3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid;

2-(N-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

5-Bromo-2-(N-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

14. (Amended) The method according to claim 1 wherein, in formula Ia, R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl

or C₁₋₆-alkoxy;


Y is $\text{>\u{N}-CH}_2\text{-}$, $\text{>\u{C}H-CH}_2\text{-}$, $\text{>\u{C}=CH-}$ or $\text{>\u{C}H-O-}$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from




wherein M₁ and M₂ independently are C or N; and

R³⁵ is hydrogen, C₁₋₆-alkyl, phenyl or benzyl; and

R³³ is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R³⁴ is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH₂)_wCOR³¹, -(CH₂)_wOH or -(CH₂)_wSO₂R³¹ wherein R³¹ is hydroxy, C₁₋₆-alkoxy or NHR³², wherein R³² is hydrogen or C₁₋₆-alkyl, and w is 0, 1 or 2; or

R³⁴ is selected from



and a pharmaceutically acceptable salt of any of the foregoing.

15. (Amended) The method according to claim 14 wherein the compound is selected from the group consisting of:

2-(4-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-pyridyl)piperazine;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-propyl)-1-piperazinyl)-3-pyridine-carboxylic acid;

2-(4-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-2-pyridinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-5-pyridinecarboxylic acid;

2-(4-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-nitrophenyl)-piperazine;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzonitrile;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzoic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(3-trifluoromethyl-2-pyridyl)piperazine;

2-(4-(2-(6,11-Dihydro-dibenzo[b,e]thiepin-11-ylidene)ethyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

2-(4-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;


6-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperazin-1-yl)-2-pyridinecarboxylic acid;

2-(4-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;


6-(4-(3-(Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-pyridine-2-carboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

16. (Amended) The method according to claim 1 wherein, in formula Ia,
R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and
Y is >N-, >CH-, >N-(C=O)- or >C=C(R⁸)-, wherein only the underscored atom participates in the ring system and R⁸ is hydrogen or C₁₋₆-alkyl; and
X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -CH₂OCH₂-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl;
and p and q are 0; and
r is 0, 1, 2, 3 or 4; and
Z is



wherein b is 0, 1, 2, 3 or 4; and
B is -CH=CR⁴⁹-, -CR⁴⁹=CH-, -C≡C-, -(C=O)-, -(C=CH₂)-, -(CR⁴⁹R⁴⁰)-, -CH(OR⁴¹)-, -CH(NHR⁴¹)-, phenylene, C₃₋₇-cycloalkylene or the completion of a bond, wherein R⁴⁹ and R⁴⁰ independently are hydrogen, C₁₋₆-unbranched alkyl, C₃₋₆-branched alkyl or C₃₋₇-cycloalkyl and wherein R⁴¹ is hydrogen or C₁₋₆-alkyl; and
U is selected from



wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

.... is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M₁ and M₂ independently are C or N; and

R^{19u} is hydrogen, C₁₋₆-alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH₂)_kCOR^{17u}, -(CH₂)_kOH or -(CH₂)_kSO₂R^{17u} wherein k is 0, 1 or 2; or

R^{16u} is selected from



and a pharmaceutically acceptable salt of any of the foregoing.

17. (Amended) The method according to claim 16 wherein the compound is selected from the group consisting of:

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(2R)-piperidinecarboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2Z)-butenyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propionyl)-(3R)-piperidine-carboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidine-carboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2E)-butenyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxopropyl)-(3R)-piperidinecarboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butynyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-dibenzo[b,f]azepin-5-ylmethyl)-1-pentyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Trifluoromethyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-1-piperazinyl)-nicotinic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopropylmethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopentylmethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic acid

(R)-1-((2R)-Methyl-3-(3-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methylpropyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-3-pyrrolidinylacetic acid;

2-(1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperazinyl)-nicotinic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1-pentyl)-3-piperidinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)piperazin-1-yl)nicotinic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxo-propyl)-3-

piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylcarbonyl)-1-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-propyl)-4-piperidinecarboxylic acid;


(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)-3-piperidinecarboxylic acid;


1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-propoxypropyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methylamino)ethyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

18. (Amended) The method according to claim 1 wherein, in formula Ia,
 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl,
 C_{1-6} -alkoxy or methylthio, $-NR^7R^8$ or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are
hydrogen or C_{1-6} -alkyl; and
Y is $>\underline{CH}-O-$ or $>\underline{CH}-S(O)_y$ wherein y is 0, 1 or 2, or $-N(R^8)-$ wherein R^8 is hydrogen or C_{1-6} -
alkyl; and
X is completion of an optional bond, ortho-phenylene, $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-$
 $CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-$
 $(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-CH_2OCH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-$
 $(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$
 $-N(R^8)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein
 R^9 is C_{1-6} -alkyl or phenyl; and
p and q independently are 0 or 1; and
r is 1, 2, 3 or 4; and
Z is selected from





wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

.... is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M_1 and M_2 independently are C or N; and

R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or

R^{16u} is selected from



and a pharmaceutically acceptable salt of any of the foregoing.

19. (Amended) The method according to claim 18 wherein, the compound is selected from the group consisting of:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;


(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

20. (Amended) The method according to claim 1 wherein, in formula Ia, R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
Y is $>\underline{N}$ -CH₂-, $>\underline{CH}$ -CH₂- or $>\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; and
X is ortho-phenylene, -O-, -S-, -C(R^7 R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and
p and q are 0; and
r is 1, 2 or 3; and

Z is selected from



wherein R^{53} is $-(CH_2)_{pp}COOH$ wherein pp is 2, 3, 4, 5 or 6; and
a pharmaceutically acceptable salt of any of the foregoing.

21. (Amended) The method according to claim 20 wherein, the compound is selected from the group consisting of:

3-(1-(3-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(2-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)ethyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Xanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)-butyric acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-2-yl)-propionic acid;

3-(1-(3-(1-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Trifluoromethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Fluoro-6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

4-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)butyric acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-2-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-propionic acid;

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-butyric acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

5-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

22. (Amended) The method according to claim 1 wherein, in formula Ia, R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{\text{N}}\text{-CH}_2\text{-}$, $>\underline{\text{CH}}\text{-CH}_2\text{-}$, $>\underline{\text{C}}=\text{CH-}$ or $>\underline{\text{CH}}\text{-O-}$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is



wherein tt and t independently are 0, 1 or 2; and

R⁶³ is H, C₁₋₆-alkyl or optionally substituted benzyl;

R⁶⁴ and R⁶⁵ independently are H, C₁₋₈-alkyl, C₃₋₇-cycloalkyl, phenyl, thienyl, benzyl, or R⁶⁴ and R⁶⁵ together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

R⁶⁶ is H or C₁₋₆-alkyl;

and a pharmaceutically acceptable salt of any of the foregoing.

23. (Amended) The method according to claim 22 wherein the compound is selected from the group consisting of:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

24. (Amended) The method according to claim 1 wherein, in formula Ia, R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl

or C₁₋₆-alkoxy; and


Y is $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$, $\text{>}\underline{\text{CH}}\text{-CH}_2\text{-}$ or $\text{>}\underline{\text{C}}\text{=CH-}$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 0, 1 or 2; and

Z is selected from



wherein D is -CH₂-, -O-, -S- or -N(R⁷)- wherein R⁷ is H or C₁₋₆-alkyl; and

R^{3m} is -(CH₂)_{mm}OH or -(CH₂)_{mp}COR⁴ wherein mm and mp are 1, 2, 3 or 4 and R⁴ is OH, NH₂, NHOH or C₁₋₆-alkoxy; and

a pharmaceutically acceptable salt of any of the foregoing.

25. (Amended) The method according to claim 24 wherein the compound is selected from the group consisting of:

3-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-pyrrolidin-1-yl)-propionic acid;

(2-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-morpholin-4-yl)-acetic acid;

(3-(10,11-Dihydro-5H-dibenz[(b,f)azepin-5-ylmethyl)-1-piperidyl)acetic acid,

or a pharmaceutically acceptable salt thereof.

26. (Amended) The method according to claim 1 wherein, in formula Ia,

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, cyano, trifluoromethyl, methylthio, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{N}$ -, $>\underline{CH}$ -, $>\underline{N}$ -(C=O)- or $>\underline{C}$ =C(R^8)-, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; and

X is ortho-phenylene, -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -CH₂OCH₂-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 0, 1, 2, 3 or 4; and


Z is



wherein b is 0, 1, 2, 3 or 4; and

B is -CH=CR⁴⁹-, -CR⁴⁹=CH-, -C≡C-, -(C=O)-, -(C=CH₂)-, -(CR⁴⁹R⁴⁰)-, -CH(OR⁴¹)-, -CH(NHR⁴¹)-, phenylene, C₃₋₇-cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and

U is



wherein R^{42} is hydrogen, -(CH₂)_cOH or -(CH₂)_dCOR⁴⁷ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein R^{47} is -OH, -NHR⁴⁴ or C_{1-6} -alkoxy wherein R^{44} is hydrogen or C_{1-6} -alkyl; and

R^{43} is cyano, $-NR^{45}R^{46}$, $-NR^{45}-V$ or $-(CHR^{48})_e-V$ wherein R^{45} and R^{46} independently are hydrogen or C_{1-6} -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R^{48} is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-NR^{45}R^{46}$ or $-COOH$, and wherein V is C_{3-8} -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
a pharmaceutically acceptable salt of any of the foregoing.

27. (Amended) The method according to claim 26 wherein the compound is selected from the group consisting of:

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-phenyl-4-piperidinecarboxylic acid;

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

4-(4-Methylphenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-anilino-4-piperidinecarboxamide;

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-phenylacetonitrile;

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinyl)-2-phenylacetic acid;


1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-cyano-4-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.



THE UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE
FEDERAL BUREAU OF INVESTIGATION
WASHINGTON, D. C. 20535

28. (Amended) The method according to claim 1 wherein, in formula Ib,
 R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
 R^{3b} is hydrogen or C_{1-3} -alkyl; and
 A_b is C_{1-3} -alkylene; and
 Y_b is $>\underline{C}H-CH_2-$, $>\underline{C}=CH-$, $>\underline{C}H-O-$, $>\underline{C}=N-$, $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system; and
 Z_b is selected from



wherein nb is 1 or 2; and

R^{11b} is hydrogen or C₁₋₆-alkyl; and

R^{12b} is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoro-methyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{14b} is -(CH₂)_{mb}OH or -(CH₂)_{tb}COR^{15b} wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein R^{15b} is -OH, NH₂, -NHOH or C₁₋₆-alkoxy; and

R^{16b} is C₁₋₆-alkyl or -B_b-COR^{15b}, wherein B_b is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene and R^{15b} is the same as above; and

... is optionally a single bond or a double bond;

and a pharmaceutically acceptable salt of any of the foregoing.

29. (Amended) The method according to claim 28 wherein the compound is selected from the group consisting of:

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

(R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid;

2-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(2-dimethylamino)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(3-dimethylamino)propyl-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(3-dimethylamino-1-methyl)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(2-dimethylaminopropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-dimethylamino-1-methylpropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

2-Fluoro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2-Methyl-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

2-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid ethyl ester;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

30. (Amended) The method according to claim 1 wherein, in formula Ic,

R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


X_c is ortho-phenylene, -O-, -S-, $-C(R^{6c}R^{7c})-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^{8c})-(C=O)-$, $-(C=O)-N(R^{8c})-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^{8c})-$, $-N(R^{8c})(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^{10c})CH_2-$, $-CH_2CH(R^{10c})-$, $-(C=O)-$, $-N(R^{9c})-$ or $-(S=O)-$ wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl; and

Y_c is C or N; and

\dots is optionally a single bond or a double bond, and \dots is a single bond when Y_c is N; and

m_c is 1, 2, 3, 4, 5 or 6; and

Z_c is $-COOR^{3c}$ or



wherein R^{3c} is H or C_{1-6} -alkyl;

and a pharmaceutically acceptable salt of any of the foregoing.

31. (Amended) The method according to claim 30 wherein the compound is selected from the group consisting of:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-carboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-carboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-carboxylic acid;

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-carboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-carboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,

and a pharmaceutically acceptable salt of any of the foregoing.


32. (Amended) The method according to claim 1 wherein, in formula Id, R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-

alkoxy; and

X_d is -O-, -S- or -S(=O)-; and

rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 ; and

Z_d is selected from



wherein R^{3d} is -(CH₂)_{md}OH or -(CH₂)_{pd}COR^{4d} wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH₂, NHOH or C₁₋₆-alkoxy;

and a pharmaceutically acceptable salt of any of the foregoing.

33. (Amended) The method according to claim 32 wherein the compound is selected from the group consisting of:

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]oxazepin-2-yl)-butanoic acid;

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]thiazepin-2-yl)-butanoic acid,

and a pharmaceutically acceptable salt of any of the foregoing.

34. (Amended) The method according to claim 1 wherein the pharmaceutical composition is in a form suitable for oral administration.